Arcturus Founder Reinstated As CEO As Settlement Ends Four-Month Feud With Former Board

The unexpected firing of Arcturus CEO Joseph Payne kicked off a bitter public battle for control of the RNA therapeutics firm after a reverse merger with Alcobra in November. The dispute now settled, the new board has reinstated Payne at Arcturus' helm.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.

The four board members who voted Arcturus Therapeutics Inc. founder Joseph Payne out of the RNA drug development firm at the end of January have been replaced under a settlement between the executive and the company announced May 29. And now, as of May 31, Payne has been reinstated as president and CEO, four months after he was unexpectedly fired.

Payne, who is Arcturus' largest shareholder with a 13.7% stake in the San Diego-based company, has demanded since the beginning...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Dr Reddy’s On Semaglutide Prospects, Capacity And There’s An IP Hearing To Watch

28 Jul 2025

• By Anju Ghangurde

Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.

Novartis Upbeat Even With Entresto Expiry Looming

17 Jul 2025

• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

17 Jul 2025

• By Lisa Takagi

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Regeneron Wins PCSK9 Court Battle Against Amgen

16 May 2025

• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Japan Results Roundup: Reduced Forex Impact, Uncertain US Tariff Outlook

13 Aug 2025

• By Lisa Takagi

Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

12 Aug 2025

• By Mary Jo Laffler

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

S&E In Brief: Launch Updates And Political Headwinds